ADMA Biologics ADMA Change in Other Liabilities
Change in Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's change in other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's change in other liabilities?
- ADMA Biologics (ADMA) reported change in other liabilities of -$340K in Q1 2026.
- How has ADMA Biologics's change in other liabilities changed year-over-year?
- ADMA Biologics's change in other liabilities increased by 47.7% year-over-year, from -$650K to -$340K.
- What is the long-term trend for ADMA Biologics's change in other liabilities?
- Over 4 years (2021 to 2025), ADMA Biologics's change in other liabilities has grown at a 55.5% compound annual growth rate (CAGR), from $219K to -$1.28M.
- What does change in other liabilities mean?
- Change in miscellaneous liabilities affecting operating cash flow.